LGALS9 and neoplasm: The ImmunoINTEL panels were complemented with drop-in IMR and IMR-L markers (PD1/PDL1, TIGIT/CD112-CD155, TIM-3/Galectin-9, SIRPa/CD47, LAG-3/HLADR) to profile the functional status of TILs, and to study the cytotoxic potential of tumor TILs.